PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32678677-12 2020 Whereas CHN-GLN group of subjects expressed only 23.17%, 21.38%, and 6.82% reduction in IL-1beta, IL-6, and sVCAM levels, respectively. Glutamine 12-15 interleukin 6 Homo sapiens 98-102 16844584-0 1997 Stimulatory effect of glutamine on human monocyte activation as measured by interleukin-6 and soluble interleukin-6 receptor release. Glutamine 22-31 interleukin 6 Homo sapiens 76-89 16844584-0 1997 Stimulatory effect of glutamine on human monocyte activation as measured by interleukin-6 and soluble interleukin-6 receptor release. Glutamine 22-31 interleukin 6 Homo sapiens 102-115 16844584-6 1997 The extracellular glutamine concentration had a significant effect on IL-6 secretion by activated human monocytes. Glutamine 18-27 interleukin 6 Homo sapiens 70-74 16844584-7 1997 The mean levels of IL-6 in 0.1 mM glutamine were only marginally higher (P = 0.54) compared to those in the absence of glutamine. Glutamine 34-43 interleukin 6 Homo sapiens 19-23 16844584-8 1997 A minimum of 0.2 mM glutamine was required to reach the maximal production of IL-6. Glutamine 20-29 interleukin 6 Homo sapiens 78-82 16844584-9 1997 At all glutamine concentrations the higher concentration of LPS (1 ng/ml) induced higher mean levels of IL-6 than the lower one (1 pg/ml). Glutamine 7-16 interleukin 6 Homo sapiens 104-108 16844584-11 1997 Our results indicate that very low levels of glutamine in plasma may impair the activation of human monocytes as measured by IL-6 secretion. Glutamine 45-54 interleukin 6 Homo sapiens 125-129 1358047-3 1992 This response of the plasma glutamine levels was significantly correlated with the production of interleukin 6 but not with that of interleukin 1, tumor necrosis factor, or interferon gamma. Glutamine 28-37 interleukin 6 Homo sapiens 97-110 35452996-7 2022 Evaluation of the cell death phenotype revealed that glutaminolysis inhibitory treatment with CB839 or a low-glutamine medium significantly promoted the proliferation of beta-galactosidase-positive and IL-6/IL-8 secretory cells among X-irradiated tumor cells, corresponding to an increase in the senescent cell population. Glutamine 109-118 interleukin 6 Homo sapiens 202-206 8651752-1 1996 OBJECTIVE: The authors studied the effects of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) on glutamine and alanine transport in isolated human hepatocytes. Glutamine 114-123 interleukin 6 Homo sapiens 46-59 8651752-1 1996 OBJECTIVE: The authors studied the effects of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) on glutamine and alanine transport in isolated human hepatocytes. Glutamine 114-123 interleukin 6 Homo sapiens 61-65 8651752-6 1996 Interleukin-6 and TNF-alpha, in combination with the synthetic glucocorticoid dexamethasone, were added to hepatocytes in culture, and the transport of radiolabeled glutamine and alanine was measured. Glutamine 165-174 interleukin 6 Homo sapiens 0-13 8651752-8 1996 RESULTS: Both IL-6 and TNF-alpha exerted a small stimulatory effect on alanine and glutamine transport. Glutamine 83-92 interleukin 6 Homo sapiens 14-18 31437565-9 2019 GLN increased the LC3-II protein expression and the number of acidic vesicular organelles, markers of autophagy, and blocked an increase in the NFkB protein expression in the nuclei and in the IL-6 gene expression caused by MEN. Glutamine 0-3 interleukin 6 Homo sapiens 193-197 32312819-7 2020 Furthermore, glutamine deprivation, as well as the antimetabolic drugs 2-deoxyglucose and metformin, also promoted the release of IL-6 and IL-8. Glutamine 13-22 interleukin 6 Homo sapiens 130-134 27579474-10 2016 Gln treatment of PBMCs overcame PfHz-induced suppression of HSP70 transcripts/protein, reduced NF-kappaB activation, and suppressed over-expression of IL-1beta, IL-6 and TNF-alpha. Glutamine 0-3 interleukin 6 Homo sapiens 161-165 28272402-3 2017 Enteral glutamine resulted in modulation of inflammatory and hormonal responses as shown by a decreased plasma interleukin 6 and cortisol levels in glutamine compared with placebo group: 5.5+-3.8 versus 11.1+-19.9 ng/l (P=0.02) for IL-6 and 386+-168.4 to 312.7+-111.7 nmol/l (P=0.03) for cortisol. Glutamine 8-17 interleukin 6 Homo sapiens 111-124 28272402-3 2017 Enteral glutamine resulted in modulation of inflammatory and hormonal responses as shown by a decreased plasma interleukin 6 and cortisol levels in glutamine compared with placebo group: 5.5+-3.8 versus 11.1+-19.9 ng/l (P=0.02) for IL-6 and 386+-168.4 to 312.7+-111.7 nmol/l (P=0.03) for cortisol. Glutamine 8-17 interleukin 6 Homo sapiens 232-236 28272402-3 2017 Enteral glutamine resulted in modulation of inflammatory and hormonal responses as shown by a decreased plasma interleukin 6 and cortisol levels in glutamine compared with placebo group: 5.5+-3.8 versus 11.1+-19.9 ng/l (P=0.02) for IL-6 and 386+-168.4 to 312.7+-111.7 nmol/l (P=0.03) for cortisol. Glutamine 148-157 interleukin 6 Homo sapiens 111-124 27815224-10 2017 Brain glutamine had a significant positive correlation with blood ammonia, IL-6, TNF-alpha and MD of various brain regions. Glutamine 6-15 interleukin 6 Homo sapiens 75-79 28105083-7 2016 The meta-analysis revealed that the levels of CRP, TNF-alpha, and IL-6 in patients supplemented with Gln were significantly lower than those in control patients, whereas the levels of IL-2 receptor were increased by Gln supplementation. Glutamine 101-104 interleukin 6 Homo sapiens 66-70 25215012-10 2011 The levels of serum ALT, AST, TBiL and TNF-alpha, IL-6 were lower in the Gln group than in the non-Gln group (P<0.01). Glutamine 73-76 interleukin 6 Homo sapiens 50-54 23498057-0 2013 Glutamine and alanine-induced differential expression of intracellular IL-6, IL-8, and TNF-alpha in LPS-stimulated monocytes in human whole-blood. Glutamine 0-9 interleukin 6 Homo sapiens 71-75 23498057-7 2013 Our investigations showed for the first time in whole blood probes, imitating best physiologically present cellular interactions, that l-glutamine caused a dose-independent inhibitory effect on IL-6 and TNF-alpha production in human monocytes stimulated with LPS. Glutamine 135-146 interleukin 6 Homo sapiens 194-198 23498057-12 2013 For the regulation of TNF-alpha, l-glutamine, l-alanine and the combination of both show a congruent and exponentiated downregulating effect during endotoxemia, for the modulation of IL-6, l-glutamine and l-alanine featured opposite regulation leading to a canceling impact of each other when recombining both amino acids. Glutamine 33-44 interleukin 6 Homo sapiens 183-187 22235107-8 2012 Interleukin-6 increased in all groups except the GLN group. Glutamine 49-52 interleukin 6 Homo sapiens 0-13 21733605-9 2011 RESULTS: There was no difference between groups in frequency and severity of diarrhoea during radiochemotherapy (p = 0.5 and p = 0.39 respectively), insulin levels significantly increased in both groups, IL-6 only in glutamine group. Glutamine 217-226 interleukin 6 Homo sapiens 204-208 21396307-9 2011 A significantly lower serum interleukin-6 level was found in comparing glutamine-enriched with standard TPN (P = 0.01), but not in interleukin-10 (P = 0.374) and tumor necrosis factor-alpha levels (P = 0.653). Glutamine 71-80 interleukin 6 Homo sapiens 28-41 27485319-12 2016 Glutamine showed inverse associations with CRP levels (r = -0.44, p < 0.05) and IL-6 concentrations (r = -0.23, p = 0.08). Glutamine 0-9 interleukin 6 Homo sapiens 83-87 25280408-11 2014 CONCLUSION: Carbohydrate or glutamine supplementation shifts the T helper (Th)1/Th2 balance toward Th1 responses after exercise at a simulated altitude of 4500 m. The nutritional strategies increased in IL-6, suggesting an important anti-inflammatory effect. Glutamine 28-37 interleukin 6 Homo sapiens 203-207 25069913-8 2014 Gln also up-regulated expression of interleukin-6, interleukin-8, MCP-1, MIP-3alpha, CCL2, CCL20, and CXCL1. Glutamine 0-3 interleukin 6 Homo sapiens 36-49 16273650-0 2005 Glutamine-supplemented total parenteral nutrition attenuates plasma interleukin-6 in surgical patients with lower disease severity. Glutamine 0-9 interleukin 6 Homo sapiens 68-81 19022976-7 2008 Arg(high)/Gln(high) decreased the production of TNFalpha, IL-1beta, IL-8, and IL-6 (each P < 0.01). Glutamine 10-13 interleukin 6 Homo sapiens 78-82 19022976-8 2008 Arg(low)/Gln(high) decreased IL-6 and IL-8 production (both P < 0.01), whereas Arg(high)/Gln(low) did not affect cytokine and NO production. Glutamine 9-12 interleukin 6 Homo sapiens 29-33 16317391-8 2005 GLN treatment increased MKP-1 peptide expression and significantly attenuated TNF-alpha and IL-6 6 h after CLP. Glutamine 0-3 interleukin 6 Homo sapiens 92-96 16273650-12 2005 However, Gln supplementation had a beneficial effect on decreasing systemic IL-6 production after surgery in patients with low admission illness severity, and lower plasma IL-6 may improve nitrogen balance in patients with abdominal surgery when Gln was administered. Glutamine 9-12 interleukin 6 Homo sapiens 76-80 16273650-12 2005 However, Gln supplementation had a beneficial effect on decreasing systemic IL-6 production after surgery in patients with low admission illness severity, and lower plasma IL-6 may improve nitrogen balance in patients with abdominal surgery when Gln was administered. Glutamine 246-249 interleukin 6 Homo sapiens 172-176 12880609-8 2003 IL-8 and IL-6 production from stimulated biopsies significantly decreased with increasing glutamine concentration from 0.5 to 10mM, (2543 [828-3634] to 1499 [282-2617] for IL-8, 62 [22-117] to 24 [12-99] for IL-6, both P<0.05), whereas IL-10 production was increased (0.7 [0.2-1.6] to 1.2 [2.6-0.5],P<0.05). Glutamine 90-99 interleukin 6 Homo sapiens 9-13 12880609-8 2003 IL-8 and IL-6 production from stimulated biopsies significantly decreased with increasing glutamine concentration from 0.5 to 10mM, (2543 [828-3634] to 1499 [282-2617] for IL-8, 62 [22-117] to 24 [12-99] for IL-6, both P<0.05), whereas IL-10 production was increased (0.7 [0.2-1.6] to 1.2 [2.6-0.5],P<0.05). Glutamine 90-99 interleukin 6 Homo sapiens 208-212 12880609-11 2003 CONCLUSIONS: Glutamine was shown in human intestinal mucosa to reduce the production of the pro-inflammatory cytokines IL-6 and IL-8, and enhance the production of the anti-inflammatory cytokine, IL-10. Glutamine 13-22 interleukin 6 Homo sapiens 119-123 12611772-0 2003 Glutamine supplementation further enhances exercise-induced plasma IL-6. Glutamine 0-9 interleukin 6 Homo sapiens 67-71 12611772-3 2003 During exercise, plasma levels of glutamine decline, and this may affect the concentration of plasma IL-6 via a decrease in IL-6 synthesis and release from muscle. Glutamine 34-43 interleukin 6 Homo sapiens 101-105 12611772-3 2003 During exercise, plasma levels of glutamine decline, and this may affect the concentration of plasma IL-6 via a decrease in IL-6 synthesis and release from muscle. Glutamine 34-43 interleukin 6 Homo sapiens 124-128 12611772-4 2003 We hypothesized that glutamine supplementation would attenuate the exercise-induced decrease in plasma glutamine concentration and, thus, further enhance levels of plasma IL-6. Glutamine 21-30 interleukin 6 Homo sapiens 171-175 12611772-7 2003 Exercise induced an 11-fold increase in plasma IL-6, which was further enhanced by glutamine (18-fold) and glutamine-rich protein (14-fold) supplementation, administered at doses that attenuated the exercise-induced decrease in plasma glutamine concentration. Glutamine 83-92 interleukin 6 Homo sapiens 47-51 12611772-7 2003 Exercise induced an 11-fold increase in plasma IL-6, which was further enhanced by glutamine (18-fold) and glutamine-rich protein (14-fold) supplementation, administered at doses that attenuated the exercise-induced decrease in plasma glutamine concentration. Glutamine 107-116 interleukin 6 Homo sapiens 47-51 11957802-6 2002 In the group of patients received TPN (with glutamine) there was a significantly increased but in comparison with group of patients without TPN, significantly lower level of IL-6 on days 1 and 7 (103.4 and 34.7 pg/ml respectively, p = 0.01). Glutamine 44-53 interleukin 6 Homo sapiens 174-178 11161457-6 2001 RESULTS: glutamine given in vivo and in vitro significantly decreased IL-6 [1.4 (0.8-8.5) vs 8.9 (1.0-43.9)] and IL-8 production [5.8 (0-51.4) vs. 53.0 (2.5-114.6), pg/mg wet tissue], median (range), both P< or =0.01, in comparison to no glutamine experiments. Glutamine 9-18 interleukin 6 Homo sapiens 70-74 12971733-2 2003 This study shows the effect of glutamine (Gln) supplementation on the production of tumor necrosis factor alpha, interleukin-10 (IL-10), and interleukin-6 (IL-6). Glutamine 31-40 interleukin 6 Homo sapiens 141-154 12971733-2 2003 This study shows the effect of glutamine (Gln) supplementation on the production of tumor necrosis factor alpha, interleukin-10 (IL-10), and interleukin-6 (IL-6). Glutamine 31-40 interleukin 6 Homo sapiens 156-160 12971733-2 2003 This study shows the effect of glutamine (Gln) supplementation on the production of tumor necrosis factor alpha, interleukin-10 (IL-10), and interleukin-6 (IL-6). Glutamine 42-45 interleukin 6 Homo sapiens 141-154 12971733-2 2003 This study shows the effect of glutamine (Gln) supplementation on the production of tumor necrosis factor alpha, interleukin-10 (IL-10), and interleukin-6 (IL-6). Glutamine 42-45 interleukin 6 Homo sapiens 156-160 12096924-0 2002 Glutamine decreases interleukin-8 and interleukin-6 but not nitric oxide and prostaglandins e(2) production by human gut in-vitro. Glutamine 0-9 interleukin 6 Homo sapiens 38-51 12096924-8 2002 RESULTS: Glutamine decreased IL-8 and IL-6 in-vitro production: 63 [2-173] vs 100 [19-177] and 37 [5-489] vs 100 [33-431], both P<0.05. Glutamine 9-18 interleukin 6 Homo sapiens 38-42 10327575-8 1999 Patients with glutamine substitution showed non significantly decreased systemic inflammation (IL-6-plasma levels, leucocytosis) and significantly faster compensation of postoperative immunosuppression (HLA-DR-monocytes). Glutamine 14-23 interleukin 6 Homo sapiens 95-99